Pds biotechnology corp (EDGE)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13
Operating expenses:
Research and development expenses

6,099

830

34,311

24,825

17,839

8,473

4,484

General and administrative expenses

10,981

2,788

17,654

14,686

8,658

4,720

2,003

Impairment charge - IPR&D

2,974

0

-

-

-

-

-

Lease termination costs

-979

0

-

-

-

-

-

Depreciation and amortization

0

27

-

-

-

-

-

Restructuring expenses

-

-

0

-

-

-

-

Impairment of machinery and equipment

-

-

0

-

-

-

-

Total operating expenses

21,034

3,646

51,966

39,512

26,498

13,194

6,488

Loss from operations

-21,034

-3,646

-51,966

-39,512

-26,498

-13,194

-6,488

Other income (expense):
Bargain purchase gain

13,334

0

-

-

-

-

-

Interest income

353

0

-

-

-

-

-

Interest income

-

-

700

212

9

2

3

Interest expense

33

3

2,180

1,203

816

183

3

Warrant remeasurement

-

-

-

0

1,879

-582

854

Other

0

0

-

163

0

0

-

Loss on extinguishment of debt

0

-185

-

-

-

-

-

Loss before income taxes

-7,380

-3,836

-53,445

-40,666

-29,186

-12,792

-7,342

Income taxes (benefit)

381

0

-2,586

-1,845

-1,107

-590

-459

Net income (loss)

-6,998

-3,836

-50,859

-38,820

-28,078

-12,201

-6,883

Comprehensive income (loss)

-6,998

-3,836

-50,859

-38,820

-28,078

-12,201

-6,883

Net loss per share, basic and diluted (in dollars per share)

1.44

1.15

-

-

-

-

-

Per share information:
Cumulative dividend on Series C , C-1 and C-2 convertible preferred stock

-

-

-

0

4,356

1,580

1,076

Net loss attributable to common stockholders

-

-

-

-38,820

-32,435

-13,782

-7,959

Loss per share attributable to common stockholders basic and diluted (in dollars per share)

-

-

-1.67

-1.34

-4.01

-8.16

-4.71

Weighted average common shares outstanding basic and diluted (in shares)

4,868

3,337

30,393

28,864

8,087

1,688

1,688